Stock ATRX ADHERA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Adhera Therapeutics, Inc.

Equities

ATRX

US00687E4061

Delayed OTC Markets
Other stock markets
 12:57:41 31/05/2024 am IST 		5-day change 1st Jan Change
0.0039 USD +2.63% Intraday chart for Adhera Therapeutics, Inc. -13.33% -87.00%
18/01 Adhera Therapeutics, Inc. Receives Written Notice from Melior Pharmaceuticals II, LLC of Election to Terminate the License Agreement CI
16/01 Adhera Therapeutics, Inc. Announces the Resignation of Zahed Subhan as Chief Executive Officer CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Adhera Therapeutics, Inc. Receives Written Notice from Melior Pharmaceuticals II, LLC of Election to Terminate the License Agreement
CI
Adhera Therapeutics, Inc. Announces the Resignation of Zahed Subhan as Chief Executive Officer
CI
Adhera Therapeutics, Inc. Announces Board Resignations
CI
Adhera Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
BigTime Penny Stocks: OTCQB Venture Market Watchlist (WOEN, ATRX, EDXC, CBDS, OMTK)
AQ
Adhera Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Thinking about buying stock in Vistagen Therapeutics, Origin Materials, MedAvail Holdings, United States Lime & Minerals, or Adhera Therapeutics?
PR
Adhera Therapeutics, Inc. announced that it has received $0.105 million in funding
CI
Adhera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Adhera Therapeutics, Inc. announced that it has received $0.1 million in funding
CI
Adhera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Adhera Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt
CI
Adhera Therapeutics, Inc. announced that it has received $0.214285 million in funding
CI
Adhera Therapeutics, Inc. announced that it has received $0.364285 million in funding
CI
Adhera Therapeutics to Collaborate with Alberta Diabetes Institute, University of Alberta to Initiate Clinical Trial of MLR-1023 in Type 1 Diabetes
CI
Adhera Therapeutics, Inc. announced that it has received $0.1 million in funding
CI
Adhera Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
Reverse Split: 1 of 20
FA
Adhera Therapeutics Announces CEO, Senior Management Changes, Plans for NASDAQ Uplist
AQ
Adhera Therapeutics, Inc. Elects Zahed Subhan as Chairman of the Board
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ATRX Stock
  4. News Adhera Therapeutics, Inc.